Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19

Onco-hematologic patients are highly susceptible to SARS-CoV-2 infection and, once infected, frequently develop COVID-19 due to the immunosuppression caused by tumor growth, chemotherapy and immunosuppressive therapy. In addition, COVID-19 has also been recognized as a further cause of HBV reactivat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagnelli, Caterina, Sica, Antonello, Creta, Massimiliano, Borsetti, Alessandra, Ciccozzi, Massimo, Sagnelli, Evangelista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144674/
https://www.ncbi.nlm.nih.gov/pubmed/35631088
http://dx.doi.org/10.3390/pathogens11050567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144674/
https://www.ncbi.nlm.nih.gov/pubmed/35631088
http://dx.doi.org/10.3390/pathogens11050567

Ejemplares similares